Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.21)
# 2,818
Out of 5,152 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $22.40 | -10.71% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $29.72 | -49.53% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $14.10 | -43.26% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $26.72 | +87.13% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $129.64 | +4.91% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.78 | +136.16% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $9.46 | +555.39% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $2.00 | +501.50% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $16.23 | +571.60% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $3.34 | +139.52% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.54 | +182.49% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.12 | +1,131.53% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $25.16 | -76.15% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.12 | +194.94% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $143.57 | -83.98% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $57.28 | -37.15% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $22.40
Upside: -10.71%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $29.72
Upside: -49.53%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $14.10
Upside: -43.26%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $26.72
Upside: +87.13%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $129.64
Upside: +4.91%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.78
Upside: +136.16%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $9.46
Upside: +555.39%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $2.00
Upside: +501.50%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $16.23
Upside: +571.60%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $3.34
Upside: +139.52%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.54
Upside: +182.49%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $8.12
Upside: +1,131.53%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $25.16
Upside: -76.15%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $7.12
Upside: +194.94%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $143.57
Upside: -83.98%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $57.28
Upside: -37.15%